Two of the biggest players in Brazil's medical diagnostics industry are likely to confront major changes in the coming months--both worth noting as global competitors seek to enter one of the largest emerging markets around. The Wall Street Journal reported that two shareholders with Diagnosticos da America SA, or DASA, have grabbed a controlling stake in the company, which has a large market share but has faced brisk executive turnover and slumping sales in recent years. And major competitor Fleury SA is potentially up for sale. Fleury has become a go-to partner for companies seeking to expand into Brazil. Last fall, for example, California's Ariosa Diagnostics partnered with Fleury to market its Harmony Prenatal test, which screens for conditions such as Down syndrome. A new owner for Fleury (potentially an investment firm) would push hard to grow the business and unlock as-yet-unmet revenue potential. Story